Literature DB >> 29052012

Effect of nasal antihistamine on secretory IgA in nasal lavage of rats.

Remzi Doğan1, Fadlullah Aksoy2, Seda Sezen Goktas3, Ilker Kocak4, Yavuz Selim Yıldırım2, Said Incir5, Orhan Özturan2.   

Abstract

The humoral IgA is an immunoglobulin which plays a defensive role for organisms on mucosal surfaces. Today, intranasal antihistamines are effectively used in the treatment of allergic rhinitis. In our study, the effect of azelastine hydrochloride-a nasal antihistaminic-on humoral IgA of the nasal mucosa has been reviewed empirically. Twenty-four female Sprague-Dawley rats were included in our study. The rats were divided into three groups randomly. Group 1(azelastine hydrochloride): rats in this group had nasal azelastine hydrochloride (0.05%) applied for 30 days at 10 µl/nostril dosage. Group 2 (saline): saline (0.09%) was applied to the rats in this group for 30 days at 10 µl/nostril dosage. Group 3 (control): no application was made throughout the study. The chemicals applied in Groups 1 and 2 were applied to both nostrils by mounting a flexible micropipette to the end of an insulin injector. At the beginning of the study, nasal lavage was performed to both nostrils of the rats in every group on the 15th and 30th day to aspirate irrigation solution (distilled water). The aspirated liquids were kept at - 80° temperature and reviewed together at the end of study. Within-group comparisons: in Group 1 (azelastine hydrochloride), the humoral IgA value on the 15th day was significantly higher than the basal value (p = 0.037). There is a significant difference between humoral IgA value on the 30th day and humoral IgA value on the 15th day (p = 0.045). In Group 2 (saline), no significant difference is available between basal, 15th day and 30th day humoral IgA values (p = 0.265). In Group 3 (control), no significant difference is available between basal, 15th day and 30th day humoral IgA values (p = 0.374). Between-group comparison: there is no significant difference in between-group humoral IgA basal values (p = 0.714). On days 15 and 30, Humoral IgA value of Group 1 was significantly higher than that of Groups 2 and 3 (p = 0.013, p = 0.024, respectively). According to the results we achieved in our study, nasal antihistaminic (azelastine hydrochloride) significantly increases the level of humoral IgA. Our study is the first one in the literature to reveal a relation between nasal antihistaminic and humoral IgA and there is a further need for clinical, randomized and prospective studies.

Entities:  

Keywords:  Azelastine hydrochloride; Nasal antihistaminic; Nasal lavage; Secretory Ig

Mesh:

Substances:

Year:  2017        PMID: 29052012     DOI: 10.1007/s00405-017-4750-1

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  34 in total

1.  Secretory IgA-mediated basophil activation. II. Roles of GTP-binding regulatory proteins and phosphatidylinositol 3-kinase.

Authors:  M Iikura; M Yamaguchi; M Miyamasu; Y Morita; T Iwase; I Moro; K Yamamoto; K Hirai
Journal:  Biochem Biophys Res Commun       Date:  1999-10-22       Impact factor: 3.575

Review 2.  Structure and function relationships in IgA.

Authors:  J M Woof; M W Russell
Journal:  Mucosal Immunol       Date:  2011-09-21       Impact factor: 7.313

Review 3.  Role of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces.

Authors:  Blaise Corthésy
Journal:  Future Microbiol       Date:  2010-05       Impact factor: 3.165

Review 4.  Role of secretory IgA in infection and maintenance of homeostasis.

Authors:  Blaise Corthésy
Journal:  Autoimmun Rev       Date:  2012-11-29       Impact factor: 9.754

5.  Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity.

Authors:  G Ciprandi; C Pronzato; G Passalacqua; V Ricca; J Grögen; G S Mela; P Varese; C Bertolini; M Bagnasco; G W Canonica
Journal:  J Allergy Clin Immunol       Date:  1996-12       Impact factor: 10.793

6.  Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine.

Authors:  Craig F LaForce; Jonathan Corren; William J Wheeler; William E Berger
Journal:  Ann Allergy Asthma Immunol       Date:  2004-08       Impact factor: 6.347

7.  Clinical practice guideline: Allergic rhinitis.

Authors:  Michael D Seidman; Richard K Gurgel; Sandra Y Lin; Seth R Schwartz; Fuad M Baroody; James R Bonner; Douglas E Dawson; Mark S Dykewicz; Jesse M Hackell; Joseph K Han; Stacey L Ishman; Helene J Krouse; Sonya Malekzadeh; James Whit W Mims; Folashade S Omole; William D Reddy; Dana V Wallace; Sandra A Walsh; Barbara E Warren; Meghan N Wilson; Lorraine C Nnacheta
Journal:  Otolaryngol Head Neck Surg       Date:  2015-02       Impact factor: 3.497

Review 8.  Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability.

Authors:  Jonathan A Bernstein
Journal:  Curr Med Res Opin       Date:  2007-10       Impact factor: 2.580

9.  Mucosal immunity in allergic rhinitis.

Authors:  G Cortesina; M T Carlevato; M Bussi; C Baldi; L Majore; C Ruffino
Journal:  Acta Otolaryngol       Date:  1993-05       Impact factor: 1.494

Review 10.  Selective IgA deficiency.

Authors:  Leman Yel
Journal:  J Clin Immunol       Date:  2010-01-26       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.